Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic (By similarity). Zusätzlich bieten wir Ihnen EML4 Proteine (4) und und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 38 products:
Human Polyclonal EML4 Primary Antibody für ICC, IF - ABIN4307859
Preusser, Berghoff, Ilhan-Mutlu, Magerle, Dinhof, Widhalm, Dieckmann, Marosi, Wöhrer, Hackl, Zöchbauer-Müller, von Deimling, Schoppmann, Zielinski, Streubel, Birner: ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. in Lung cancer (Amsterdam, Netherlands) 2013
Show all 3 Pubmed References
Human Monoclonal EML4 Primary Antibody für IHC (p), ELISA - ABIN565390
Radtke, Rezaie, Kugler, Zabel, Schultz, Vollmer, Goldmann, Lang: Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics. in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2010
Mutation testing at diagnosis is feasible in the vast majority of patients with Stage IV adenocarcinoma of the lung. Patients with EGFR (zeige EGFR Antikörper) or EML4ALK mutation and those who received pemetrexed maintenance had better clinical outcomes.
Our analysis indicated that ALK-EML4 positive non-small-cell lung cancers comprised a unique subgroup of adenocarcinomas with distinct clinicopathological characteristics. Incidence of ALK positivity was found to be higher in females and never smokers.
Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors
identified EML4-ALK gene rearrangement in expanded circulating tumor cells from a patient with ALK-positive lung adenocarcinoma
Knockdown of SMYD2 as well as treatment with a SMYD2 inhibitor in two NSCLC cell lines with an EML4-ALK gene significantly attenuated the phosphorylation levels of the EML4-ALK protein.
The EML4-ALK-mediated upregulation of HIF1alpha, HK2 and glycolytic metabolism was also highly active in vivo as demonstrated by fluorodeoxyglucose-positron emission tomography imaging of xenografts grown from EML4-ALK-positive NSCLC cells.
We assessed the prevalence of EML4-ALK rearrangement gene measured by immunohistochemistry in an unselected population-based consecutive cohort of patients with adenocarcinoma of the lung (ACL (zeige ACLY Antikörper)), and the correlation with smoking history, thyroid transcription factor 1 (TTF1 (zeige NKX2-1 Antikörper)), gender and age
Our findings show that group EML4-ALK variants 3a/b in non-small cell lung cancer may be a major source of ALK inhibitor resistance in the clinic.
EML4-ALK rearrangement detection in malignant pleural effusions is a complementary method for EML4-ALK detection. VETANA and qRT-PCR are more appropriate for MPE detection. EML4-ALK rearrangement in pleural effusions has a predictive value for treatment.
EML4-ALK-positive lung cancer is often highly progressive.
May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic (By similarity).
echinoderm microtubule-associated protein-like 4
, echinoderm microtubule associated protein like 4
, echinoderm microtubule-associated protein-like 4-like
, restrictedly overexpressed proliferation-associated protein
, ropp 120